Drug intelligence / Profile preview

APSTZD 2

Development stage: Unknown
Lead developer: Apsen Farmacêutica
Administration: Oral

Overview

**APSTZD 2** is an undisclosed investigational oral APSTZD treatment variant being developed by Apsen Farmacêutica for insomnia disorder. It is one of four APSTZD-labelled experimental interventions in the randomized, double-blind, double-dummy Phase II TINA study, which compares APSTZD variants with zolpidem extended-release and placebo in adults with chronic insomnia. The publicly available trial record does not disclose APSTZD 2's chemical identity, dose, formulation characteristics beyond oral tablets, or molecular mechanism of action.

Beyond the preview

Go deeper on APSTZD 2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APSTZD 2.

Explore the full profile